徳島大学 教育・研究者情報データベース(EDB)

1. (英) Momoko Chikugo / (日) 筑後 桃子 / (読) ちくご ももこ

   役割	任意
   貢献度	任意
   学籍番号	推奨	****

2. (英) Mayu Sebe / (日) 瀬部 真由 / (読) せべ まゆ

   役割	任意
   貢献度	任意
   学籍番号	推奨	****

3. 堤 理恵

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. (英) Marina Iuchi / (日) 井内 茉莉奈 / (読) いうち まりな

   役割	任意
   貢献度	任意
   学籍番号	推奨	****

5. 岸 潤

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. 黒田 雅士

   役割	任意
   貢献度	任意
   学籍番号	推奨

7. 原田 永勝

   役割	任意
   貢献度	任意
   学籍番号	推奨

8. 西岡 安彦([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])

   役割	任意
   貢献度	任意
   学籍番号	推奨

9. 阪上 浩([徳島大学.大学院医歯薬学研究部.医学域.栄養科学部門.医科栄養学系.代謝栄養学]/[徳島大学.糖尿病臨床・研究開発センター])

   役割	任意
   貢献度	任意
   学籍番号	推奨

(英) Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism.

(英) Tofacitinib is the first Janus Kinase (JAK) inhibitor to treat moderately to severely active RA. In this study, we investigated whether the effect of tofacitinib have any effects on body composition in mice and female patients with RA. Female C57BL/6 mice fed with a high-fat diet were treated with 30 mg/kg/day tofacitinib or vehicle for 70 days. Following treatment, trunk muscle, subcutaneous fat, and visceral fats were measured using X-ray computed tomography CT scan. Glucose tolerance and insulin sensitivity were assessed. In female RA patients treated with biological disease modified anti-rheumatic-drugs (biological DMARDs) or tofacitinib (n=4 per group), we also evaluated the body composition after 3 months from the start of treatment initiation using bioelectrical impedance analysis. Treatment with tofacitinib did not affect the body weight, and body composition in C57BL/6 mice. It also did not affect glucose, and insulin tolerance in mice. In patients with RA, treatment with biological DMARDs did not affect the body composition whereas the muscle mass was unchanged after receiving tofacitinib and the fat mass was significantly increased. J. Med. Invest. 65:166-170, August, 2018.

1. (英) PublicationType: Journal Article